UNSPSC 51453007: Piperazine dihydrobromide

This classification denotes an antihelminthic agent with the molecular formula C4H10N2.2BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AD5RF7D2AU, chemically known as piperazine, hydrobromide (1:2), but more generally known as piperazine dihydrobromide, which bears US NIH Compound Identifier 3017157. European Medicines Agency schedules piperazine dihydrobromide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03841MIG.

Most nations, for tariff purposes, schedule piperazine dihydrobromide under HS 29335990. SMILES: C1CNCCN1.BR.BR.

UNSPSC 51453007 Piperazine dihydrobromide is a Commodity code that in recent state and local procurement shows little activity directly aligned with its nominal chemical scope. The code appears in a small set of opportunities focused on pharmaceutical procurement, medical supplies, and pharmacy benefit programs, but none of the recent solicitations directly specify piperazine dihydrobromide or chemical precursors as a line item. State and local buying under this code, when activity does occur, centers on bulk pharmaceutical acquisition through cooperative purchasing vehicles, medical and first aid supplies for emergency response, and pharmacy benefit program design. Issuing bodies include state health and human services departments, county health agencies, city fire departments, and multistate cooperative purchasing alliances. The Texas Health and Human Services Commission and Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) are principal players in recent activity, with smaller single-jurisdiction procurements from Seminole County, Florida and the City of Tampa.

Recent activity concentrates in Texas, Florida, and Minnesota. The Minnesota Department of Administration's MMCAP issued an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to supply through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a July 26, 2023 response deadline and quarterly deliveries to the Seminole County Community Health Building. The City of Tampa released IFB 26P00145 on March 25, 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000 and a sheltered-market set-aside for certified Small Local Business Enterprises. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The code shows limited direct relevance to active procurement; firms should verify specific solicitation language before investing pursuit resources.